The aim of the present review is to report the ABC transporters that are involved in MDR following various HDAC inhibitor treatments in a range of cancer cell lines, particularly emphasizing the upregulation of P-gp and suggesting a careful use of HDAC inhibitors in clinical treatment. Here, PGP is linked to cancer.